ReviewCurrent hypertension reports2021
Integrating Measures of Myocardial Fibrosis in the Transition from Hypertensive Heart Disease to Heart Failure.
Review in Current hypertension reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 19 citations in OpenAlex.
- Paradoxical Trends in Hypertensive Heart Disease: Rising Burden in High-Sociodemographic-Index Regions Despite Healthcare Quality-An Age-Period-Cohort Analysis, 1992-2021.Journal of cardiovascular development and disease · 2026Article
- Lactate dehydrogenase-to-Albumin Ratio (LAR) predicts mortality in critically ill patients with hypertensive heart failure: A MIMIC-IV database analysis.Clinics (Sao Paulo, Brazil) · 2026Article
- Sociodemographic and sex differences in the global burden of hypertensive heart disease, 1990-2021: a population-based analysis.Tropical medicine and health · 2025Article
- Assessment of left ventricular systolic function and pathological changes using layer-specific strain in rats with myocardial hypertrophy at various disease stages.The international journal of cardiovascular imaging · 2025Article
- Salidroside impedes Ang II-infused myocardial fibrosis by activating the SIRT1-Nrf2 pathway.Iranian journal of basic medical sciences · 2025Article
- Global prevalence and disability-adjusted life years of hypertensive heart disease: A trend analysis from the Global Burden of Disease Study 2019.Journal of global health · 2024Article
- Sex, gender, and subclinical hypertensiveorgan damage-heart.Journal of human hypertension · 2023Review
- Clinical Utility of Strain Imaging in Assessment of Myocardial Fibrosis.Journal of clinical medicine · 2023Review
- The prevalence, disability-adjusted life years, and mortality of hypertensive heart disease and its attributable risk factors: results from the Global Burden Disease study 2019.Archives of medical science : AMS · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review aims to summarize recent developments in identifying and quantifying both the presence and amount of myocardial fibrosis by imaging and biomarkers. Further, this review seeks to describe in general ways how this information may be used to identify hypertension and the transition to heart failure with preserved ejection fraction. RECENT
findingsRecent studies using cardiac magnetic resonance imaging highlight the progressive nature of fibrosis from normal individuals to those with hypertension to those with clinical heart failure. However, separating hypertensive patients from those with heart failure remains challenging. Recent studies involving echocardiography show the subclinical myocardial strain changes between hypertensive heart disease and heart failure. Lastly, recent studies highlight the potential use of biomarkers to identify those with hypertension at the greatest risk of developing heart failure. In light of the heterogeneous nature between hypertension and heart failure with preserved ejection fraction, an integrated approach with cardiac imaging and biomarker analysis may enable clinicians and investigators to more accurately characterize, prevent, and treat heart failure in those with hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.